relatlimab (BMS-986016) / BMS 
Welcome,         Profile    Billing    Logout  
 4 Diseases   51 Trials   51 Trials   979 News 


«12345678910111213...1314»
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Enrollment closed, Trial completion date, Trial primary completion date:  iSCORE: Immunotherapy Sequencing in COlon and REctal Cancer (clinicaltrials.gov) -  May 26, 2022   
    P2,  N=25, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2022 --> Feb 2022 Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Sep 2023 | Trial primary completion date: Mar 2022 --> Dec 2022
  • ||||||||||  Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date, Combination therapy:  Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18) (clinicaltrials.gov) -  May 20, 2022   
    P1,  N=63, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Sep 2023 | Trial primary completion date: Mar 2022 --> Dec 2022 Trial completion date: Apr 2022 --> Apr 2023 | Trial primary completion date: Mar 2021 --> Sep 2022
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date, Tumor mutational burden, Metastases:  NCI-2018-01517: Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma (clinicaltrials.gov) -  Apr 29, 2022   
    P2,  N=20, Recruiting, 
    Initiation date: Mar 2022 --> Jun 2022 | Trial primary completion date: Mar 2030 --> Jul 2027 Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2022 --> Apr 2023
  • ||||||||||  relatlimab (BMS-986016) / BMS, Ono Pharma, Opdivo (nivolumab) / Ono Pharma, BMS
    LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers. (Available On Demand; 216) -  Apr 28, 2022 - Abstract #ASCO2022ASCO_1621;    
    High LAG3 was found in almost a quarter of tumor samples and significantly associated with other immune checkpoints with FDA-approved drugs. Ongoing studies combining LAG3 inhibitors and specific immune checkpoint inhibitors may yield more clinical benefit if individualized immunomic transcript interrogation is undertaken, rather than population-based approaches without employment of rationally combined agents matched to each patient’s cancer.
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Trial completion date, Trial primary completion date, Combination therapy, IO biomarker, Metastases:  Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Na (clinicaltrials.gov) -  Apr 27, 2022   
    P2,  N=42, Recruiting, 
    Ongoing studies combining LAG3 inhibitors and specific immune checkpoint inhibitors may yield more clinical benefit if individualized immunomic transcript interrogation is undertaken, rather than population-based approaches without employment of rationally combined agents matched to each patient’s cancer. Trial completion date: Oct 2022 --> Jul 2023 | Trial primary completion date: Oct 2022 --> Jul 2023
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS
    Trial primary completion date, IO biomarker:  CA209-906: Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer (clinicaltrials.gov) -  Apr 20, 2022   
    P1,  N=32, Active, not recruiting, 
    Trial completion date: Oct 2022 --> Jul 2023 | Trial primary completion date: Oct 2022 --> Jul 2023 Trial primary completion date: Feb 2022 --> Jan 2023
  • ||||||||||  Remicade (infliximab) / J&J, Renflexis (infliximab-abda) / Yuhan Corp, Biogen, Ewopharma, Samsung, Organon
    Enrollment open, Adverse events, Combination therapy, Metastases:  PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma (clinicaltrials.gov) -  Apr 8, 2022   
    P2,  N=36, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Apr 2022 --> Apr 2024 | Trial primary completion date: Mar 2022 --> Apr 2024 Not yet recruiting --> Recruiting
  • ||||||||||  relatlimab (BMS-986016) / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Trial completion date, Trial primary completion date, Metastases:  Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy (clinicaltrials.gov) -  Mar 28, 2022   
    P2,  N=40, Recruiting, 
    Trial completion date: May 2025 --> Oct 2026 | Trial primary completion date: Apr 2022 --> Aug 2023 Trial completion date: Mar 2023 --> Mar 2026 | Trial primary completion date: Mar 2022 --> Mar 2025